A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Withdrawn before enrolling · Phase 1/Phase 2
Conditions studied: Advanced Cancer
In brief
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Key facts
- Study ID
- NCT04158700
- Run by
- Eli Lilly and Company
- People needed
- 0
- Starts
- 2019-12-05
- Expected to finish
- 2023-05-11
- Last updated by the study team
- 2020-02-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study [for example, nivolumab, pembrolizumab, atezolizumab]
- Participants must be willing to have tumor biopsies
- Participants must have adequate organ function
- Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- Participants must be able to swallow tablets
- Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days
You may not qualify if…
- Participants must not have moderate or severe cardiovascular disease
- Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc)
- Participants must not have an active infection requiring treatment
Where it is running
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- CHU de Besancon Hopital Jean Minjoz — Besançon, France
- Gustave Roussy — Villejuif, France
- Institut Catala d'Oncologia — L'Hospitalet de Llobregat, Barcelona, Spain
- Hospital Clinic I Provincial — Barcelona, Spain
- Hospital Madrid Norte Sanchinarro — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.